Drug-Drug Interactions Associated with Length of Stay and Cost of Hospitalization
Open Access
- 7 September 2009
- journal article
- Published by Frontiers Media SA in Journal of Pharmacy & Pharmaceutical Sciences
- Vol. 12 (3) , 266-272
Abstract
Purpose To evaluate the prevalence of drug-drug interactions (DDI) in prescriptions of hospitalized patients and to identify risk factors associated. Methods A retrospective cross-sectional analysis of prescription data and medical records from a public hospital in Brazil was conducted to identify potential DDI. An inappropriate drug combination was identified and classified with a standard drug interaction source. The main diagnoses were classified with Charlson Comorbidity Index (CCI). Sex, age, polypharmacy and length of stay, among other variables, were correlated with the frequency of potential DDI. Results The study included 589 patients and 3,585 prescriptions. Thirty-seven percent of the patients were exposed to at least one potential interaction during their stay in the hospital. The most frequent interacting pair was Digoxin+Furosemide (11%). In univariate analysis, several variables were associated with DDI, including sex, age, number of prescribed drugs, length and cost of hospitalization and CCI. Multivariate analysis showed that the adjusted odds of being prescribed a potential DDI among patients in polypharmacy was almost five-fold that of patients taking less than five drugs. Further, length of stay, CCI and cost of hospitalization were independently associated with DDI. Conclusion Analysis of prescription data found that a substantial number of potential DDI were identified. Results of this study indicate that DDI is associated with number of prescribed drugs, increased duration of stay in the hospital and cost, which suggest that DDI are a significant clinical and economic problem. Potential damage to patients could be avoided.Keywords
This publication has 16 references indexed in Scilit:
- Potential Drug Interactions in Cancer Patients Receiving Supportive Care ExclusivelyJournal of Pain and Symptom Management, 2008
- Potentially inappropriate prescribing to hospitalised patientsPharmacoepidemiology and Drug Safety, 2007
- Effect of drug‐test interactions on length of hospital stayPharmacoepidemiology and Drug Safety, 2006
- Hospitalisations and emergency department visits due to drug–drug interactions: a literature reviewPharmacoepidemiology and Drug Safety, 2006
- Drug-drug interactions among recently hospitalised patients – frequent but mostly clinically insignificantEuropean Journal of Clinical Pharmacology, 2005
- Potential for drug interactions in hospitalized cancer patientsCancer Chemotherapy and Pharmacology, 2005
- Potential drug–drug interactions in the medication of medical patients at hospital dischargeEuropean Journal of Clinical Pharmacology, 2003
- Incidence and risk of potential adverse drug interactions in the emergency roomResuscitation, 2001
- Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness ModelJournal of the American Pharmaceutical Association, 2001
- Adverse Drug Events in Hospitalized PatientsExcess Length of Stay, Extra Costs, and Attributable MortalityJAMA, 1997